Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of...

Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs
Letters of Intent

HARBIN, China, June 6 /Xinhua-PRNewswire-FirstCall/ -- Renhuang
Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the Company"), a
leading pharmaceutical company in the People's Republic of China ("PRC"),
today announced the successful completion of its Tianma pills trade show in
Harbin, China on May 29, 2008.
Tianma pills, one of the Chinese traditional medicines Renhaung
manufactories, are approved for the treatment of headaches. The primary active
ingredient in Tianma pills, Rhizoma Gastrodiae, is released into the blood
stream, supplying nutrients that relax brain nerves and speed up blood
circulation. Since Tianma pills are highly effective with no side effects,
they are one of the top-selling headache drugs in China by volume.
The trade show attracted about 100 agencies and representatives from major
retail chains around the country. Renhuang signed letters of intent for
distribution agreements with two separate pharmaceutical retail chain stores:
Harbin Renmin Tongtai Pharmaceutical and Baofeng Pharmaceutical. The
agreements are expected to bring an additional RMB 20 million in sales for
Renhuang. Harbin Renmin Tongtai Pharmaceutical has 57 stores, which are all
located in Heilongjiang province. Baofeng Pharmaceutical has over 1000 stores,
covering Heilongjiang, Shanghai, Nanjing and Hangzhou.
"We intend to increase our sales growth going forward by focusing on
promoting our products through marketing and improving our product pipeline by
finding the best product mix," said Mr. Shao-ming Li, Chairman and CEO of
Renhaung Pharmaceuticals, Inc. "In addition, we are confident that sales of
Tianma pills for Fiscal Year 2008 will surpass sales of $1.97 million recorded
in 2007."
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western,
traditional Chinese medicines (TCM), and branded pharmaceuticals, using its
GMP-certified facilities in China. The Company's GMP-certified manufacturing
facilities, containing cutting-edge technologies and advance equipment, are
capable of producing as many as 200 types of pharmaceuticals. Additionally,
Renhuang distributes raw materials and finished pharmaceutical products using
its extensive distribution channels and third party distributors throughout
China. The Company's distribution network includes over 3,000 sales
representatives in 70 sales centers across 24 districts, covering over 50% of
the greater China. The Company also exports its products to Russia and
Southeast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward-looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in The People's Republic of China,
variations in cash flow, reliance on collaborative retail partners and on new
product development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or undetected
flaws and defects in products, and other risk factors detailed in reports
filed with the Securities and Exchange Commission from time to time.
For more information, please contact:

Renhuang Pharmaceuticals, Inc.
Ms. Shuang Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com

CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Web: http://www.ccgelite.com

SOURCE Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. - Ms. Shuang Tan, IR Contact,
+86-451-5392-5461, or ir@renhuang.com; CCG Elite Investor Relations Inc. - Mr.
Crocker Coulson, President, +1-646-213-1915 (New York), or
crocker.coulson@ccgir.com